First-in-Human Clinical Trial for B-cell Lymphoma Using “Armored” CAR T Cells Opens at Roswell Park

Chimeric antigen receptor (CAR) T-cell therapy is emerging as an effective therapeutic strategy for patients with B-cell lymphoid cancers. Over the last five years, it has been used for patients with relapsed diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Recently, CAR T therapy was approved by the FDA to treat patients with relapsed/refractory chronic lymphocytic leukemia (CLL). With currently available CAR T therapy products, long-term cancer control can be observed in around 40% of patients. There is a need to develop better forms of CAR T therapies to maximize their potential.

"Armored" CART-cells are a new generation of CAR T products that are being evaluated in clinical trials. Roswell Park Comprehensive Cancer Center is conducting a first-in-human Phase I trial of CD19-Targeted Chimeric Antigen Receptor Modified T Cells Genetically Engineered to Secrete Interleukin 12 (IL-12). This enhanced form of immunotherapy was developed by Roswell Park scientists in collaboration with scientists at Memorial Sloan Kettering. 

The T cells used in this trial will be manufactured at Roswell Park's expanded state-of-the-art GMP Engineering & Cell Manufacturing Facility for the first time. "We will have the infrastructure, the process, the support structure to not only manufacture cells for therapy but also to be able to support a clinical trial and have the resources in place to be able to infuse these therapies into a patient,” says Christopher Choi, PhD, MBA Senior Vice President of Industry Partnerships and Technical Director of GMP Facility at Roswell Park.

Related Presenters